A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)

被引：0
|
作者：
Ahluwalia, Manmeet [1 ]
Fallah, Jaleh [2 ]
Peereboom, David [3 ]
Schilero, Cathy [3 ]
Ali, Assad [3 ]
Forst, Deborah [4 ]
Wong, Eric [5 ]
Wen, Patrick [6 ]
Reardon, David [6 ]
机构：
[1] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
[2] Taussig Canc Inst, Cleveland, OH USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RBTT-08
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [41] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    NEURO-ONCOLOGY, 2023, 25
  • [42] BEVACIZUMAB ALONE VERSUS BEVACIZUMAB PLUS IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA: A NATIONWIDE POPULATION-BASED STUDY
    Lee, Yeonhu
    Roh, Tae Hoon
    Kim, Se-Hyuk
    NEURO-ONCOLOGY, 2023, 25
  • [43] Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
    Reardon, David A.
    Brandes, Alba A.
    Omuro, Antonio
    Mulholland, Paul
    Lim, Michael
    Wick, Antje
    Baehring, Joachim
    Ahluwalia, Manmeet S.
    Roth, Patrick
    Baehr, Oliver
    Phuphanich, Surasak
    Sepulveda, Juan Manuel
    De Souza, Paul
    Sahebjam, Solmaz
    Carleton, Michael
    Tatsuoka, Kay
    Taitt, Corina
    Zwirtes, Ricardo
    Sampson, John
    Weller, Michael
    JAMA ONCOLOGY, 2020, 6 (07) : 1003 - 1010
  • [44] TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE plus BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Peereboom, David
    Lathia, Justin
    Sinyuk, Maksim
    Brewer, Cathy
    Ahluwalia, Manmeet
    Vogelbaum, Michael
    NEURO-ONCOLOGY, 2016, 18 : 19 - 19
  • [45] TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE plus BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Peereboom, David
    Lathia, Justin
    Alban, Tyler
    Mohammadi, Alireza
    Ahluwalia, Manmeet
    Brewer, Cathy
    Vogelbaum, Michael
    NEURO-ONCOLOGY, 2018, 20 : 12 - 13
  • [46] TARGETING MYELOID DERIVED SUPPRESSOR CELLS: PHASE 0/1 TRIAL OF LOW DOSE CAPECITABINE plus BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Peereboom, David M.
    Vogelbaum, Michael
    Mohammadi, Alireza
    Alban, Tyler
    Brewer, Cathy
    Ahluwalia, Manmeet
    Sinyuk, Maksim
    Lathia, Justin
    NEURO-ONCOLOGY, 2017, 19 : 31 - 31
  • [47] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
    Kaseb, Ahmed Omar
    Pestana, Roberto Carmagnani
    Vence, Luis M.
    Blando, Jorge M.
    Singh, Shalini
    Ikoma, Naruhiko
    Raghav, Kanwal Pratap Singh
    Sakamuri, Divya
    Girard, Lauren
    Tan, Dongfeng
    Vauthey, Jean-Nicolas
    Tzeng, Ching-Wei David
    Aloia, Thomas A.
    Chun, Yun Shin
    Yao, James C.
    Wolff, Robert A.
    Allison, James Patrick
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENTIN RECURRENT GLIOBLA STOMA: THE DUTCH BELOB STUDY
    Taal, Walter
    Oosterkamp, H.
    Walenkamp, Annemieke
    Beerenpoot, Lucas
    Hanse, Monique
    Buter, Jan
    Honkoop, Aafke
    Boerman, Dolf
    de Vos, Filip
    Jansen, R.
    van der Berkmortel, Franchette
    Brandsma, Dieta
    Enting, Roelien
    Kros, Johan
    Bromberg, Jacoline
    van Heuvel, Irene
    Smits, Marion
    van der Holt, Ronnie
    Vernhout, Rene
    van den Bent, Martin
    NEURO-ONCOLOGY, 2013, 15 : 83 - 84
  • [49] Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients
    Reardon, David A.
    Nayak, Lakshmi
    Peters, Katherine B.
    Clarke, Jennifer Leigh
    Jordan, Justin T.
    De Groot, John Frederick
    Nghiemphu, Phioanh Leia
    Kaley, Thomas Joseph
    Colman, Howard
    Gaffey, Sarah C.
    Caruso, Victoria
    Debruyne, Myriam Bednarek
    Bhavsar, Chinmay
    Molinaro, Annette M.
    Smith, Timothy
    Severgnini, Mariano
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS
    Reardon, David
    Molinaro, Annette
    Peters, Katherine
    Clarke, Jennifer
    Jordan, Justin
    de Groot, John
    Nghiemphu, Phioanh
    Kaley, Thomas
    Colman, Howard
    McCluskey, Christine
    Smith, Timothy
    Cote, David
    Severgnini, Mariano
    Yearley, Jennifer
    Zhao, Qing
    Blumenschein, Wendy
    Duda, Gabriel
    Muzikansky, Alona
    Jain, Rakesh
    Wen, Patrick
    Nayak, Lakshmi
    NEURO-ONCOLOGY, 2020, 22 : 40 - 40
12345